Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Deraya University
University Medical Center Groningen
Nagoya City University
University of Washington
Samsung Medical Center
Institut Català d'Oncologia
Rawalpindi Medical College
Zhejiang Cancer Hospital
The University of Hong Kong-Shenzhen Hospital
National Institute of Oncology, Hungary
Peking University Third Hospital
Peking University Third Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shandong Cancer Hospital and Institute
Xijing Hospital
Vanderbilt University Medical Center
Karolinska Institutet
University of California, San Francisco
Shanghai Zhongshan Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University